Sorrento Therapeutics Plans to Cut Development of Its Coronavirus Vaccine if the Leaders' Vaccines Work

Brian Orelli, PhD, The Motley Fool
·5-min read

While multiple vaccines have completed phase 3 clinical trials or will in the coming months, Sorrento's lead vaccine, T-VIVA-19, hasn't even entered clinical trials yet. Brian Orelli: You do have a vaccine that you're working on called T-VIVA-19.